Pulse Biosciences Schedules Second Quarter 2024 Financial Results Conference Call for August 12, 2024
Pulse Biosciences (Nasdaq: PLSE), a company specializing in Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, has announced its plans to release second quarter 2024 financial results on Monday, August 12, 2024, after the market closes. The company will host a conference call at 1:30pm PT / 4:30pm ET on the same day to discuss the results. Investors can join the call by dialing 1-877-704-4453 (domestic) or 1-201-389-0920 (international). A live and recorded webcast of the event will also be available on the company's investor relations website.
Pulse Biosciences (Nasdaq: PLSE), un'azienda specializzata nella tecnologia Nanosecond Pulsed Field Ablation™ (nsPFA™), ha annunciato i suoi piani per pubblicare i risultati finanziari del secondo trimestre del 2024 lunedì, 12 agosto 2024, dopo la chiusura del mercato. L'azienda organizzerà una chiamata conferenza alle 13:30 PT / 16:30 ET dello stesso giorno per discutere i risultati. Gli investitori possono partecipare alla chiamata componendo il numero 1-877-704-4453 (nazionale) o 1-201-389-0920 (internazionale). Sarà inoltre disponibile una diretta e una registrazione dell'evento sul sito web delle relazioni con gli investitori dell'azienda.
Pulse Biosciences (Nasdaq: PLSE), una empresa especializada en la tecnología Nanosecond Pulsed Field Ablation™ (nsPFA™), ha anunciado sus planes de publicar los resultados financieros del segundo trimestre de 2024 el lunes 12 de agosto de 2024, después del cierre del mercado. La empresa organizará una llamada de conferencia a las 1:30 PM PT / 4:30 PM ET el mismo día para discutir los resultados. Los inversores pueden unirse a la llamada marcando el 1-877-704-4453 (nacional) o el 1-201-389-0920 (internacional). También se dispondrá de una transmisión en vivo y grabada del evento en el sitio web de relaciones con inversores de la empresa.
Pulse Biosciences (Nasdaq: PLSE)는 나노초 펄스 필드 절제(nsPFA™) 기술에 전문화된 회사로, 2024년 2분기 재무 결과를 2024년 8월 12일 월요일 장 마감 후 발표할 계획이라고 발표했습니다. 동일한 날 오후 1시 30분 PT / 오후 4시 30분 ET에 결과를 논의하기 위해 콘퍼런스 콜을 개최합니다. 투자자들은 1-877-704-4453 (국내) 또는 1-201-389-0920 (국제)로 전화를 걸어 콜에 참여할 수 있습니다. 또한 회사의 투자자 관계 웹사이트에서 이벤트의 실시간 및 녹화된 웹캐스트도 제공될 예정입니다.
Pulse Biosciences (Nasdaq: PLSE), une entreprise spécialisée dans la technologie d'Ablation par Champ Pulsé en Nanosecondes™ (nsPFA™), a annoncé ses projets de publication des résultats financiers du deuxième trimestre 2024 le lundi 12 août 2024, après la fermeture du marché. L'entreprise organisera une conférence téléphonique à 13h30 PT / 16h30 ET le même jour pour discuter des résultats. Les investisseurs peuvent rejoindre l'appel en composant le 1-877-704-4453 (national) ou le 1-201-389-0920 (international). Une diffusion en direct ainsi qu'un enregistrement de l'événement seront également disponibles sur le site web des relations investisseurs de l'entreprise.
Pulse Biosciences (Nasdaq: PLSE), ein Unternehmen, das auf Nanosecond Pulsed Field Ablation™ (nsPFA™)-Technologie spezialisiert ist, hat die Pläne für die Veröffentlichung der Finanzergebnisse für das zweite Quartal 2024 am Montag, den 12. August 2024, nach Börsenschluss bekannt gegeben. Das Unternehmen wird am selben Tag um 13:30 Uhr PT / 16:30 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu diskutieren. Investoren können sich über die Nummer 1-877-704-4453 (inlands) oder 1-201-389-0920 (international) in die Konferenz einwählen. Eine Live-Übertragung und eine aufgezeichnete Webcast des Ereignisses werden auch auf der Website der Investor Relations des Unternehmens verfügbar sein.
- None.
- None.
Investors interested in listening to the conference call may do so by dialing 1-877-704-4453 for domestic callers or 1-201-389-0920 for international callers. A live and recorded webcast of the event will be available at http://investors.pulsebiosciences.com/.
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary CellFX® nsPFA™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. Pulse Biosciences is now headquartered in
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240729277595/en/
Investors:
Pulse Biosciences, Inc.
Burke T. Barrett, President and CEO
IR@pulsebiosciences.com
Or
Gilmartin Group
Philip Trip Taylor
415.937.5406
philip@gilmartinir.com
Source: Pulse Biosciences, Inc.
FAQ
When will Pulse Biosciences (PLSE) release its Q2 2024 financial results?
What time is the Pulse Biosciences (PLSE) Q2 2024 earnings conference call?
How can investors listen to Pulse Biosciences' (PLSE) Q2 2024 earnings call?
What is Pulse Biosciences' (PLSE) primary technology focus?
